Thalidomide, VEGF inhibitors, tyrosine kinase inhibitors, and matrix metalloproteinases are currentlyÂ under investigation as single agents to treat Kaposi sarcoma.

- Intra-lesional nivolumab for cutaneous Kaposi sarcoma

- Pomalidomide with liposomal doxorubicin for refractory Kaposi sarcoma

- Pembrolizumab for relapsed and refractory HIV related neoplasms

- Ipilimumab and nivolumab for advanced HIV related neoplasms

- Nelfinavir for endemic, classic, and HIV-related Kaposi sarcoma

- Valganciclovir for HIV-related Kaposi sarcoma, particularly patients with immune reconstitution syndrome

- Recombinant EphB4-HAS fusion protein

- Selumetinib